Chapter 30 Doing business the sustainable Novo Nordisk Way
Restricted access

This case study focuses on Novo Nordisk, a well-known Danish pharmaceutical company, which is changing the world of diabetes, obesity and hemophilia care as well as hormone replacement and growth hormone therapy. The company's key sustainability initiatives are presented through an analysis of secondary data such as websites, annual reports, books, etc. The analysis shows that Novo Nordisk makes decisions according to the "Novo Nordisk Way" and translates this decision-making philosophy into the "Triple Bottom line", a combined balance of the dimensions of sustainability: environmental, social, and economic considerations. Further, the company puts a lot of focus on behaving responsibly towards their stakeholder groups: customers, employees, communities, suppliers and investors. Novo Nordisk defines success by the solutions they bring to society in benefiting the health and well-being of people living with certain chronic diseases. They also focus on chronic diseases' prevention and broadening access to affordable care for patients worldwide.

You are not authenticated to view the full text of this chapter or article.

Access options

Get access to the full article by using one of the access options below.

Other access options

Redeem Token

Institutional Login

Log in with Open Athens, Shibboleth, or your institutional credentials

Login via Institutional Access

Personal login

Log in with your Elgar Online account

Login with you Elgar account
Handbook